Bendamustine
Also known as Bendamustine Hydrochloride, Ribomustin, SDX-105, or Treakisym.
General information
Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.[1][2][3]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
- Multiple myeloma
- T-cell lymphoma
Patient drug information
- Bendamustine (Treanda) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 7 of the package insert[1]
- Bendamustine (Treanda) patient drug information (UpToDate)[5]
References
- Drug index
- Chemotherapy
- Vesicant chemotherapy
- Nitrogen mustards
- Alkylating agents
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Multiple myeloma medications
- Non-Hodgkin lymphoma medications
- T-cell lymphoma medications